ACRV
Acrivon Therapeutics, Inc.Company Information
- Company Name
- Acrivon Therapeutics, Inc.
- CIK
- CIK0001781174
- Category
- <br>Emerging growth company
- Ticker: Exchange
- ACRV: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- ACRV
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-01-14
- Last sale
- 2025-05-01
- Shares purchased (TTM)
- 67,832
- Shares sold (TTM)
- 548,886
Institutional Sentiment
- As of
- 2026-03-31
- Institutional shares owned
- 15,193,810
- Shares outstanding
- 38,724,803
- Ownership
- 39.24%
Earnings Market Reaction
- Filing date
- 2026-08-12
- Price on filing date
- —
- 1-month reaction
- 23.84%
- 3-month reaction
- Pending
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 41 | 34 | 41 | 35 | 42 | 39 | 40 | 43 | 46 | 25 | 36 | 30 | ||||||
| Short Term Investments | 49 | 64 | 77 | 94 | 96 | 110 | 140 | 144 | 135 | 85 | 91 | 112 | ||||||
| Prepaid Expense And Other Assets Current | 2 | 1 | 2 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | ||||||
| Assets Current | 91 | 99 | 120 | 130 | 138 | 151 | 182 | 189 | 182 | 112 | 130 | 144 | ||||||
| Property Plant And Equipment Net | 4 | 5 | 5 | 5 | 5 | 5 | 4 | 5 | 3 | 3 | 3 | 2 | ||||||
| Operating Lease Right Of Use Asset | 2 | 2 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | 4 | ||||||
| Long Term Investments | - | - | - | 5 | 10 | 15 | 5 | 15 | 40 | - | - | - | ||||||
| Restricted Cash Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Other Assets Noncurrent | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 1 | - | - | 0 | - | ||||||
| Assets | 99 | 108 | 130 | 145 | 159 | 176 | 197 | 215 | 231 | 121 | 138 | 151 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 1 | 1 | 2 | 1 | 1 | 4 | 1 | 2 | 1 | 2 | 5 | 2 | ||||||
| Accrued Liabilities And Other Liabilities | 9 | 9 | 12 | 13 | 11 | 9 | 15 | 12 | 9 | 6 | 7 | 7 | ||||||
| Operating Lease Liability Current | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Liabilities Current | 11 | 11 | 16 | 15 | 13 | 14 | 17 | 15 | 11 | 9 | 13 | 9 | ||||||
| Operating Lease Liability Noncurrent | 1 | 1 | 2 | 2 | 2 | 2 | 3 | 3 | 3 | 4 | 4 | 4 | ||||||
| Liabilities | 12 | 12 | 17 | 17 | 16 | 16 | 20 | 18 | 15 | 13 | 17 | 13 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 399 | 389 | 387 | 384 | 381 | 377 | 373 | 370 | 368 | 241 | 238 | 236 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | -0 | -0 | -0 | -0 | ||||||
| Retained Earnings Accumulated Deficit | -312 | -294 | -275 | -256 | -238 | -217 | -197 | -174 | -152 | -133 | -116 | -97 | ||||||
| Stockholders Equity | 87 | 96 | 113 | 129 | 143 | 160 | 177 | 197 | 216 | 108 | 121 | 138 | ||||||
| Liabilities And Stockholders Equity | 99 | 108 | 130 | 145 | 159 | 176 | 197 | 215 | 231 | 121 | 138 | 151 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | ||||||
| Common Stock Shares Issued | 43 | 39 | 32 | 32 | 31 | 31 | 31 | 31 | 31 | 23 | 23 | 22 | ||||||
| Shares Outstanding | 43 | 39 | 32 | 32 | 31 | 31 | 31 | 31 | 31 | 23 | 23 | 22 | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialAcrivon Therapeutics, Inc. (ACRV) — SEC Financial Statements & Analysis
Acrivon Therapeutics, Inc. (ACRV) is a pharmaceutical preparations company. Acrivon Therapeutics, Inc. trades on Nasdaq as: ACRV. Acrivon Therapeutics, Inc. (ACRV)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-12. Based on that filing, Acrivon Therapeutics, Inc. carries a market cap of $74.48M, a P/E ratio of -1.00x, a P/B ratio of 0.86x, an enterprise value of $32.87M, and an EV/EBITDA multiple of -0.43x. On profitability, it posts a Return on Equity (ROE) of -64.63%, a Return on Assets (ROA) of -57.61%, and a Return on Invested Capital (ROIC) of -107.22%. Per share, it reports EPS of $-1.77, diluted EPS of $-1.77, free cash flow per share of $-1.53, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of -13.65% year-over-year and EPS growth of -20.63% year-over-year. On the balance sheet, it maintains a current ratio of 7.99x, a quick ratio of 7.86x, working capital of $80.05M, a debt-to-equity ratio of 0.14x, a debt ratio of 0.13, an interest coverage ratio of -17.03x, free cash flow of $-64.14M (TTM), and net debt of $-41.61M. Figures sourced from SEC EDGAR.
- Market Cap
- $74.48M
- P/E TTM
- -1.00x
- EPS TTM
- $-1.77
- P/B TTM
- 0.86x
- ROE TTM
- -64.63%
- ROA TTM
- -57.61%
- Debt To Equity
- 0.14x
- Free Cash Flow TTM
- $-64.14M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Acrivon Therapeutics, Inc. in?
Acrivon Therapeutics, Inc. (ACRV) operates in the Pharmaceutical Preparations industry.
What exchange does ACRV trade on?
Acrivon Therapeutics, Inc. (ACRV) trades on the Nasdaq.
When was Acrivon Therapeutics, Inc. (ACRV)'s most recent SEC filing?
Acrivon Therapeutics, Inc. (ACRV)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-12.
What is ACRV's market cap?
Acrivon Therapeutics, Inc. (ACRV) has a market capitalization of $74.48M as of 2026-06-30.
What is ACRV's EPS (earnings per share)?
Acrivon Therapeutics, Inc. (ACRV)'s trailing twelve month EPS is $-1.77 as of 2026-06-30.
What is ACRV's ROE (return on equity)?
Acrivon Therapeutics, Inc. (ACRV)'s trailing twelve month Return on Equity (ROE) is -64.63% as of 2026-06-30.
What is ACRV's ROA (return on assets)?
Acrivon Therapeutics, Inc. (ACRV)'s trailing twelve month Return on Assets (ROA) is -57.61% as of 2026-06-30.
What is ACRV's ROIC (return on invested capital)?
Acrivon Therapeutics, Inc. (ACRV)'s trailing twelve month Return on Invested Capital (ROIC) is -107.22% as of 2026-06-30.
What is ACRV's EV/EBITDA?
Acrivon Therapeutics, Inc. (ACRV)'s trailing twelve month EV/EBITDA is -0.43x as of 2026-06-30.